Insider buying last 90 days
No open-market insider purchases were filed for PLSE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PLSE insider filing, plotted on the chart in Gekko.Open PLSE in Gekko
NASDAQ: PLSE
Pulse Biosciences (PLSE) Stock Analysis & Forecast
Oct 12 close
$52.45−1.36 (−2.5%)
Gekko Brief
AI summaryOct 12 closePulse Biosciences this week drew attention for clinical progress rather than financial results. The company announced it had reached its enrollment target of 164 evaluable patients in the NANOPULSE-AF pivotal IDE study for its nPulse Cardiac Catheter System, three months ahead of schedule, a milestone covered repeatedly across multiple releases. Separately, the nPulse technology was set to be featured at the 21st Annual International VT Symposium 2026, and the company granted inducement equity awards to two new employees under Nasdaq Listing Rule 5635(c)(4), with options priced at $49.98 per share.
The stock closed at $52.45, down 2.5% on the day, but remains above both its 50-day average of $48.95 and its 200-day average of $28.82, with the shorter average above the longer one. The GekkoIndex reads 55.4, placing it in the Neutral zone, down 3.2 points over five sessions. Price sits 10.6% above Gekko Fair Value of $47.44.
Over the next 20 trading days, earnings are due on 4 November 2026, after the close, 23 days away and within a typical holding window; the last report showed a loss of $0.36 per share against a $0.31 estimate and an 11.9% reaction. Analyst consensus among 6 firms rates the stock a buy, with a consensus target of $56.50. Seasonality over 5 years shows a 10.3% average 20-day return from this point, rising in 4 of those years. No insider, Congress or unusual options activity appears in the current window.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Pulse Biosciences price vs fair value
Close $52.45200-day averageGekko Fair Value $47.44
Pulse Biosciences quick facts
- Market cap
- $3.63B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.18
- Revenue, TTM
- $1.19M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.57
- Volume
- 434,412 avg 517,815
- 1-year return
- +172.5%
- Typical daily move
- ±5.8%
- Typical 20-day move
- ±13.7%
- 50-day average
- $48.95
- 200-day average
- $28.82
- Next earnings
- Nov 4 after close
- Shares outstanding
- 71.32M
Pulse Biosciences swing-trade checklist
Pulse Biosciences scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $52.45 is above the 50-day ($48.95) and 200-day ($28.82) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55.4, Neutral
Reading 55.4 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
10.6% above
Price is 10.6% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+10.3% on average
From this point in the calendar, the next 20 trading days averaged +10.3% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Pulse Biosciences stock chart and price history
Pulse Biosciences closed at $52.45 on Oct 12, 2026, +172.5% over the past year, inside a 52-week range of $12.56 to $58.90.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −1.2%
- 3 months
- +106.0%
- 6 months
- +177.2%
- 1 year
- +172.5%
The full PLSE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PLSE in Gekko
Follow Pulse Biosciences through every session
Put PLSE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PLSE in GekkoFree for 7 days. No credit card required.
About Pulse Biosciences
Pulse Biosciences develops bioelectric medical technology centered on its CellFX System, a software-controlled console platform. The system applies a proprietary approach called Nano-Pulse Stimulation, which sends extremely short, nanosecond-length electrical pulses into targeted cells. The aim is to destroy chosen cells through this electrical effect rather than heat, leaving surrounding tissue structures intact. The CellFX System is used to address a range of medical conditions through this cell-clearing method.
The company's work centers on this single platform technology, with the CellFX System applied across different treatment uses rather than a broad product catalog. Its approach is built around the nanosecond pulse method as the mechanism behind its medical applications.
Pulse Biosciences was first incorporated in 2014 under the name Electroblate, Inc., and took on its current name, Pulse Biosciences, Inc., in December 2015. The company is headquartered in Hayward, California. Its shares are listed on the NASDAQ under the ticker PLSE.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- pulsebiosciences.com
Pulse Biosciences GekkoIndex: the smart money zone
Pulse Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.4, in the Neutral zone, down 3.2 points over five sessions.
55.4Neutral
Down 3.2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 25 | −1.3% | +8.3% | ||
| Accumulation | 202 | +5.3% | +12.4% | ||
| Neutral (current zone) | 406 | +0.9% | +6.9% | ||
| Distribution | 42 | −1.9% | −8.1% | ||
| Selling | 7 | Too few readings yet | |||
Average PLSE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the PLSE price, zone by zone.Track PLSE in Gekko
Is Pulse Biosciences stock overvalued? Gekko Fair Value
Pulse Biosciences trades 10.6% above Gekko Fair Value of $47.44, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Pulse Biosciences shares are worth, recalculated every trading day.
$47.44
Gekko Fair Value, Oct 10, 2026
10.6% Overvalued
At the end of Aug 2026 the price was 20.0% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PLSE in Gekko
Pulse Biosciences insider and Congress trading
No open-market insider purchases were filed for Pulse Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PLSE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PLSE, plotted on the chart in Gekko.Open PLSE in Gekko
Pulse Biosciences earnings: next date and track record
Pulse Biosciences reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 3 of its last 7 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- −$0.35
- Revenue estimate
- $605K
3 of 7reports beat the EPS estimate
±7.9%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Pulse Biosciences reported an active Q2 2026, emphasizing progress in enrollment for its nPulse Cardiac Catheter IDE study, strong clinical enthusiasm for its nsPFA technology, and continued investment in clinical programs. Management highlighted the unique attributes of their nanosecond pulsed field ablation (nsPFA) platform—non-thermal targeted energy, rapid lesion delivery, and durable lesions—and positioned the technology as highly differentiated versus existing ablation modalities. Financials showed modest product revenue ($434k) while GAAP and non-GAAP losses widened year-over-year due to increased clinical investment and headcount; cash and cash equivalents increased to $101.6M at quarter end following recent financing. Key operational priorities are completing IDE enrollment (progressing ahead of timeline), pursuing CE Mark pathways, advancing catheter partnerships, and building market value for Vybrance through a partnership, while maintaining operating discipline. Management was confident and optimistic throughout the prepared remarks and Q&A; analysts focused on enrollment pace, mapping integration, capital usage, procedural efficiency, and expected commercialization build-out.
- Guidance
- Management provided operational guidance that quarterly operating expenses are expected to remain in the reported non-GAAP range as they continue to invest in clinical programs. They also stated they have at least five quarters of cash runway relative to forward spend and that CE Mark submission efforts are on track. No explicit revenue or EPS guidance was provided.
- Risks flagged
- Risks mentioned or implied include: increased operating losses and higher clinical spend; reliance on rapid and representative trial enrollment (site caps and potential skew); regulatory review timing and requirements; need to attract and scale commercial/sales resources upon approval; competition from established players and other PFA technologies; and general uncertainties disclosed in SEC filings.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.36 est −$0.31 | $434K est $533K | +11.9% |
| May 4, 2026 | −$0.24 est −$0.22 | $400K est $250K | −10.5% |
| Feb 19, 2026 | −$0.18 est −$0.21 | $264K est $150K | −15.9% |
| Nov 5, 2025 | −$0.29 est −$0.31 | $86K est $225K | −2.1% |
| Aug 12, 2025 | −$0.28 est −$0.26 | — est $500K | +12.8% |
| May 8, 2025 | −$0.25 | $1.66M | +2.3% |
| Mar 27, 2025 | −$0.31 est −$0.24 | $1.66M | +5.1% |
| Oct 30, 2024 | −$0.21 est −$0.24 | — | +2.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Pulse Biosciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Pulse Biosciences is $56.50, +7.7% from the last close, from 6 firms rating the stock in the last 90 days.
$56.50consensus 12-month target, +7.7% from the last close
Now $52.45Avg $56.50
Low $35High $73
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 6 | BTIG | $70 | +33.5% |
| Oct 6 | Canaccord Genuity | $58 | +10.6% |
| Sep 23 | BTIG | $70 | +33.5% |
| Sep 9 | Freedom Capital Markets | $73 | +39.2% |
| Aug 17 | Needham | $58 | +10.6% |
+6.9%average 20-day move after past Neutral readings
+10.3%average move over the next 20 trading days in the last 5 years
±5.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Pulse Biosciences seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Pulse Biosciences averaged +10.3% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +7.9% | 3 of 5 |
| Next 10 trading days | +4.8% | 4 of 5 |
| Next 15 trading days | +6.4% | 4 of 5 |
| Next 20 trading days | +10.3% | 4 of 5 |
| Next 30 trading days | +3.9% | 3 of 5 |
For scale, PLSE’s typical 20-trading-day move in either direction is about 13.7%.
Pulse Biosciences market cap and key statistics
Pulse Biosciences’s market cap is $3.63B and revenue of $1.19M over the last twelve months.
Valuation
- Market cap
- $3.63B
- EPS, TTM
- −$1.18
- Gekko Fair Value
- $47.44
Trading
- Volume
- 434,412
- Avg volume, 20 days
- 517,815
- 52-week high
- $58.90
- 52-week low
- $12.56
- Shares outstanding
- 71.32M
Financials
- Revenue, TTM
- $1.19M
- Profit margin
- 0%
- Return on equity
- -78.5%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.57
- Typical daily move
- ±5.8%
- Typical 20-day move
- ±13.7%
Pulse Biosciences stock news this week
Coverage of Pulse Biosciences this week reads positive: 13 positive, 1 neutral and 1 negative headlines.
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FinancialContent, Oct 9
- Pulse Biosciences (NasdaqCM:PLSE) Stock PriceSimply Wall Street, Oct 8
- Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026Business Wire, Oct 8
- Pulse Biosciences stock reaches 164 patient study targetAD HOC NEWS, Oct 8
- Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation TreatmentInvesting News Network, Oct 7
- Pulse Biosciences hits 164-patient enrollment target in NANOPULSE-AF pivotal IDE studyTradingView, Oct 7
Pulse Biosciences peers
Pulse Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Pulse Biosciences stock FAQ
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $3.63B at the Oct 12, 2026 close of $52.45, with 71.32M shares outstanding.
What is the Pulse Biosciences stock forecast?
The consensus analyst 12-month price target for Pulse Biosciences is $56.50, +7.7% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Pulse Biosciences stock overvalued or undervalued?
On Gekko’s estimate Pulse Biosciences is overvalued: the Oct 12, 2026 close of $52.45 is 10.6% above Gekko Fair Value of $47.44. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Pulse Biosciences report earnings next?
Pulse Biosciences is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of −$0.35 per share on revenue of $605K. Pulse Biosciences beat the earnings estimate in 3 of its last 7 reports, moving 7.9% on average across the report.
What is Pulse Biosciences’s 52-week high and low?
Pulse Biosciences’s 52-week high is $58.90 and its 52-week low is $12.56; it closed at $52.45 on Oct 12, 2026, +172.5% over the past year.
Is Pulse Biosciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Pulse Biosciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.